Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500344 · ClinicalTrials.gov registry record · Phase 1
CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00500344 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 17 participants.
The verdict
NCT00500344, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
Interventions
- DRUG Lucentis (ranibizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500344
The ClinicalTrials.gov registry entry for NCT00500344 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lucentis (ranibizumab) is the first listed.
NCT00500344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00500344 about?
NCT00500344 is a clinical study titled "CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography". CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
What is the current status of trial NCT00500344?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2007-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00500344?
The interventions under investigation include: Lucentis (ranibizumab) (DRUG).
Who is sponsoring clinical trial NCT00500344?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.